Skip to content Skip to footer
Subscribe Now

NEWS

Roche
The EC Approves Roche’s Evrysdi Tablet for Spinal Muscular Atrophy
Shots: The EC has approved label extension of Evrysdi (5mg oral tablet) for pts with spinal muscular atrophy (SMA) Approval was based on P-I study assessing Evrysdi 5mg tablet vs oral solution, showing bioequivalence with comparable efficacy & safety; data was presented at SMA Europe 2024 Evrysdi, an SMN2 splicing modifier, treats SMA caused by…
June 5, 2025
Eli Lilly and Camurus
Eli Lilly Licenses Camurus’ FluidCrystal Technology to Advance Long-Acting Incretin Products
Shots: Camurus has granted Eli Lilly exclusive global rights to research, develop, manufacture, & commercialize long-acting incretin drugs using Camurus’ FluidCrystal tech for cardiometabolic diseases  As per the deal, Camurus will receive ~$290M in upfront, development & regulatory milestones as well as $580M in sales-based milestones & global net sales-based tiered royalties in mid-single digits…
June 5, 2025
TelaBio
TELA Bio Launches OviTex Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair in the EU
Shots: TELA Bio has launched OviTex Inguinal in the EU for laparoscopic & robotic-assisted inguinal hernia repair; OviTex Inguinal to be showcased at EHS 2025 OviTex Inguinal is available in 2 trocar-compatible configurations, consisting of 3 or 4 layer anatomically shaped devices that provide surgeons with flexible options designed to meet pts, technique, or procedure-specific needs…
June 4, 2025
Zoetis
Zoetis Launches AI Masses to Detect Skin and Lymph Lesions
Shots: Zoetis has launched AI Masses for its Vetscan Imagyst analyzer to detect neoplastic cells in animals; AI Masses is available in North America starting Jun 2, 2025 AI Masses uses advanced deep learning algorithms to identify & classify common skin/subcutaneous masses & lymph node lesions in real time, improving point-of-care access & client satisfaction,…
June 4, 2025
Takeda
Takeda’s Adcetris Regimen Receives the EC’s Approval to Treat Newly Diagnosed Hodgkin Lymphoma
Shots: The EC has approved Adcetris (brentuximab vedotin) + ECADD (etoposide, cyclophosphamide, doxorubicin, dacarbazine & dexamethasone) to treat adults with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma following CHMP’s positive opinion in Apr 2025 Approval was based on P-III (HD21) trial assessing Adcetris + ECADD vs escalated doses of BEACOPP in above pts,…
June 4, 2025
Load more